Anna, 26, felt fine. Her last Pap smear was normal. But when her clinic added HPV testing, doctors found a high-risk strain silently present. She wasn’t alone.
In Turkey, cervical cancer rates have stayed high despite screening. Many women still get diagnosed too late. Traditional Pap smears catch cell changes — but only after they’ve started. What if we could see the threat earlier?
Now, a large study of over 83,000 cervical smears reveals a shift. The real danger isn’t just abnormal cells — it’s the virus that comes before them.
HPV is the hidden trigger behind most cervical cancers.
Most people think of HPV as common and harmless. And yes, many strains go away on their own. But certain types — like HPV 16 and 18 — can stay in the body for years. They’re like a quiet engine running in the background, slowly damaging cells.
Imagine your cervix as a factory floor. HPV is the faulty manager who keeps letting broken machines run. At first, everything looks okay. But over time, mistakes build up. Cells start to change. That’s when a Pap smear finally flags a problem — often years too late.
This study shows we can catch the faulty manager much earlier — by testing for the virus itself.
The silent shift in young women
The data comes from a major hospital in Istanbul, tracking cervical screening from 2014 to 2025. Most women were screened with Pap smears. But starting in 2020, some also got HPV tests — first for high-risk types, then for specific strains.
Here’s what changed: while abnormal cell rates dropped with age, HPV rates spiked in women under 30.
One in five women aged 21–25 tested positive for high-risk HPV. Even more surprising — the 18–20 age group had the highest rate of cell abnormalities, nearly 13%. That’s more than double the national average in many countries.
This flips old assumptions. We used to think cervical risk climbed slowly after 30. Now, the danger may start much earlier — and silently.
This doesn’t mean this treatment is available yet.
The test isn’t standard across Turkey. Only a subset of patients received it, based on doctor referral or test availability. But when they did test, the results were clear: HPV DNA testing found more at-risk women than cytology alone.
And when biopsies followed up abnormal smears, the match was strong. Over 80% of high-grade Pap results linked to serious tissue changes. But many HPV-positive women had normal smears — meaning the virus was present long before cells changed.
A better way to catch risk early
So why not test for HPV first? Some countries already do. In the U.S. and parts of Europe, primary HPV testing is now the preferred method. It’s more sensitive. It finds risk earlier.
But in Turkey, Pap smears remain the main tool. This study adds strong local evidence that it may be time to change.
Think of it like smoke versus fire. A Pap smear sees the flames — the damaged cells. HPV testing smells the smoke — the virus that could start the fire.
Finding smoke early gives you time to act. You can monitor more closely. You can catch problems at stage zero.
Experts say this data fills a critical gap. Most HPV studies come from Western countries. This one reflects Turkish women’s real-world risk — and shows young adults may need more attention, not less.
What this means for women today
If you’re under 30, this matters. You may feel healthy. Your last smear may have been normal. But without HPV testing, you could still carry a high-risk strain.
Should you ask for the test? Not all clinics offer it yet. But if you have a family history, a past abnormal result, or just want more clarity, talk to your doctor.
Some barriers remain. The test costs more. Labs need training. And not all health plans cover it. But as more data like this emerges, change becomes harder to ignore.
The study had limits. It looked back at old records. It didn’t follow every woman long-term. And HPV testing only began in recent years, so the full picture is still forming.
But the trend is clear: young women are at higher risk than we thought — and we have better tools to protect them.
What happens next
More clinics in Turkey are starting to adopt HPV testing. National guidelines are under review. If this trend continues, primary HPV screening could become standard — especially for women under 30.
Larger studies are needed. But for now, this data lights the path. The future of cervical screening may not be about waiting for cells to change.
It may be about stopping the fire before it starts.
